Namzaric
Product Images NDC 0456-1229

15 FDA label images from Allergan, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Namzaric (NDC 0456-1229). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Allergan, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Namzaric 01)

Structural Formula (Namzaric 01)
Chemical structure diagram of the active ingredient shown, including functional groups such as an amine and methyl groups, along with a hydrochloride moiety. The diagram displays a bicyclic framework with specified substituents.*
FDA Label Image

Donepezil Hydrochloride (Namzaric 02)

Donepezil Hydrochloride (Namzaric 02)
Chemical structure of Namzaric showing the molecular arrangement of its active components, including aromatic rings, piperazine ring, and methoxy groups, along with a hydrochloride component.*
FDA Label Image

Figure 1: Time Course Of The Change From Baseline In Sib Score For Patients Completing 24 Weeks Of Treatment. (Namzaric 03)

Figure 1: Time Course Of The Change From Baseline In Sib Score For Patients Completing 24 Weeks Of Treatment. (Namzaric 03)
A line graph depicting the mean change from baseline in SIB score over 24 weeks of treatment. Two lines compare Memantine HCl ER 28 mg/AChEI and Placebo/AChEI groups, showing clinical improvement or decline with error bars for SEM at various time points over weeks.*
FDA Label Image

Figure 2: Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Sib Scores. (Namzaric 04)

Figure 2: Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Sib Scores. (Namzaric 04)
A line chart showing the cumulative percentage of patients on the y-axis and SIB change from baseline on the x-axis, comparing Memantine HCl ER 28 mg/AChEI treatment versus placebo/AChEI. The chart illustrates two curves representing patient response distributions for the treatment and placebo groups.*
FDA Label Image

Figure 3: Time Course Of The Cibic-plus Score For Patients Completing 24 Weeks Of Treatment. (Namzaric 05)

Figure 3: Time Course Of The Cibic-plus Score For Patients Completing 24 Weeks Of Treatment. (Namzaric 05)
This line graph compares the CIBIC-Plus scores over 24 weeks of treatment for Namzaric (Memantine HCl ER 28 mg/AChEI) versus placebo with AChEI. It shows mean scores with error bars, indicating clinical improvement and decline zones, plotted against weeks of treatment from 0 to 24.*
FDA Label Image

Figure 4: Distribution Of Cibic-plus Ratings At Week 24. (Namzaric 06)

Figure 4: Distribution Of Cibic-plus Ratings At Week 24. (Namzaric 06)
A bar chart comparing percentages of patients across CIBIC-Plus Rating categories between Memantine HCl ER 28 mg/AChEI and Placebo/AChEI groups. Categories include Marked Improvement, Moderate Improvement, Minimal Improvement, No Change, Minimal Worsening, Moderate Worsening, and Marked Worsening. The chart visualizes the distribution of patient responses for each treatment.*
FDA Label Image

Figure 5. Time Course Of The Change From Baseline In Sib Score For Patients Completing 6 Months Of Treatment. (Namzaric 07)

Figure 5. Time Course Of The Change From Baseline In Sib Score For Patients Completing 6 Months Of Treatment. (Namzaric 07)
A line graph depicting SIB (Severe Impairment Battery) change from baseline over 6 months of drug treatment. The graph compares donepezil hydrochloride 10 mg/day, showing clinical improvement, with placebo, showing clinical decline. The vertical axis represents the mean change from baseline, and the horizontal axis represents months of drug treatment at 0, 3, and 6 months.*
FDA Label Image

Figure 6. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Sib Scores. (Namzaric 08)

Figure 6. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Sib Scores. (Namzaric 08)
A cumulative percentage curve graph comparing the percentage of patients over changes from baseline in SIB (Severe Impairment Battery) scores. The graph plots two groups: donepezil hydrochloride 10 mg/day (black circles) and placebo (open squares). The x-axis shows SIB change from baseline, and the y-axis shows the cumulative percentage of patients, illustrating differences in cognitive response between treatment and placebo.*
FDA Label Image

Figure 7. Time Course Of The Change From Baseline In Adcs-adl-severe Score For Patients Completing 6 Months Of Treatment. (Namzaric 09)

Figure 7. Time Course Of The Change From Baseline In Adcs-adl-severe Score For Patients Completing 6 Months Of Treatment. (Namzaric 09)
Line graph comparing ADCS-ADL mean change from baseline over 6 months of drug treatment between donepezil hydrochloride 10 mg/day and placebo. The vertical axis measures change with labels for clinical improvement and decline. The graph shows the donepezil group declines less than placebo over time.*
FDA Label Image

Figure 8. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Adcs-adl-severe Scores. (Namzaric 0a)

Figure 8. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Adcs-adl-severe Scores. (Namzaric 0a)
A cumulative percentage of patients line graph comparing donepezil hydrochloride 10 mg/day to placebo. The x-axis shows ADCS-ADL Change from Baseline ranging from +20 to -20, and the y-axis shows the cumulative percentage of patients from 0% to 100%. The donepezil group shows a higher cumulative percentage of improvement compared to placebo.*
FDA Label Image

Ndc 0456-1207-30 Rx Only30 Capsules Namzaric®(memantine And Donepezilhydrochlorides) Extended-release Capsules 7 mg/10 mg Per Capsuleabbvie (Namzaric 0b)

Ndc 0456-1207-30 Rx Only30 Capsules Namzaric®(memantine And Donepezilhydrochlorides) Extended-release Capsules 7 mg/10 mg Per Capsuleabbvie (Namzaric 0b)
Label for Namzaric extended-release capsules containing 7 mg memantine and 10 mg donepezil hydrochlorides per capsule. The package contains 30 capsules and is labeled by Allergan, Inc. It includes storage instructions and prescription-only status with NDC 0456-1207-30.*
FDA Label Image

Ndc 0456-1214-30 Rx Only30 Capsules Namzaric®(memantine And Donepezil Hydrochlorides) Extended-release Capsules 14 mg/10 mg Per Capsuleabbvie (Namzaric 0c)

Ndc 0456-1214-30 Rx Only30 Capsules Namzaric®(memantine And Donepezil Hydrochlorides) Extended-release Capsules 14 mg/10 mg Per Capsuleabbvie (Namzaric 0c)
Namzaric 14 mg/10 mg extended-release capsules label showing product name, strengths, and active ingredients memantine and donepezil hydrochlorides. The label states it contains 30 capsules and is manufactured by Allergan, Inc. Additional storage, dosage, and safety information is also present.*
FDA Label Image

Ndc 0456-1221-30 Rx Only30 Capsules Namzaric®(memantine And Donepezilhydrochlorides) Extended-release Capsules 21 mg/10 mg Per Capsuleabbvie (Namzaric 0d)

Ndc 0456-1221-30 Rx Only30 Capsules Namzaric®(memantine And Donepezilhydrochlorides) Extended-release Capsules 21 mg/10 mg Per Capsuleabbvie (Namzaric 0d)
Namzaric 21 mg/10 mg extended-release capsules label from Allergan, Inc. The label indicates 30 capsules per container, with active ingredients memantine and donepezil hydrochlorides. It includes storage instructions, dosage information, and manufacturer details. The packaging features a barcode and NDC 0456-1221-30.*
FDA Label Image

Ndc 0456-1228-30 Rx Only30 Capsules Namzaric®(memantine And Donepezil Hydrochlorides) Extended-release Capsules 28 mg/10 mg Per Capsuleabbvie (Namzaric 0e)

Ndc 0456-1228-30 Rx Only30 Capsules Namzaric®(memantine And Donepezil Hydrochlorides) Extended-release Capsules 28 mg/10 mg Per Capsuleabbvie (Namzaric 0e)
Namzaric extended-release capsules containing memantine and donepezil hydrochlorides, 28 mg/10 mg per capsule, in a package of 30 capsules. The label is by Allergan, Inc. and includes storage instructions and dosage information, along with the NDC 0456-1228-30. The capsules are distributed by Allergan USA, Inc.*
FDA Label Image

Titration Packndc 0456-1229-29 Namzaric®(memantine And Donepezil Hydrochlorides)extended-release Capsules Week 1 7mg/10 mg Week 2 14mg/10 mg Week 3 21mg/10 mg Week 4 28mg/10 mg This Titration Pack Includes:namzaric® Extended Release Capsulesfor Your First 4 Weeks Of Therapy. For Detailed Dosing Instructions, See Inside Panel. This Titration Pack Is Not To Be Refilled. (Namzaric 0f)

Titration Packndc 0456-1229-29 Namzaric®(memantine And Donepezil Hydrochlorides)extended-release Capsules Week 1 7mg/10 mg Week 2 14mg/10 mg Week 3 21mg/10 mg Week 4 28mg/10 mg This Titration Pack Includes:namzaric® Extended Release Capsulesfor Your First 4 Weeks Of Therapy. For Detailed Dosing Instructions, See Inside Panel. This Titration Pack Is Not To Be Refilled. (Namzaric 0f)
Namzaric titration pack packaging label for extended-release capsules containing memantine and donepezil hydrochlorides. The label details a four-week titration schedule with weekly dosages of 7 mg/10 mg, 14 mg/10 mg, 21 mg/10 mg, and 28 mg/10 mg. The pack is distributed by Allergan, Inc., includes capsules for initial four weeks of therapy, and features the National Drug Code (NDC) 0456-1229-29.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.